Biodegradable- Versus Durable-Polymer DES in ST-Segment Elevation Myocardial Infarction: Time to Update Our a Priori Beliefs?
- PMID: 33727006
- DOI: 10.1016/j.jcin.2021.01.031
Biodegradable- Versus Durable-Polymer DES in ST-Segment Elevation Myocardial Infarction: Time to Update Our a Priori Beliefs?
Keywords: ST-segment elevation myocardial infarction; acute coronary syndrome; biodegradable polymer; drug-eluting stents(s); percutaneous coronary intervention.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Byrne has received research funding to the institution of prior employment from Celonova Biosciences; and has received research or educational funding to the institution of current employment from Abbott Vascular, Biosensors, Biotronik, and Boston Scientific; but has not received personal payments from any pharmaceutical company or device manufacturer. Dr. Coughlan has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.JACC Cardiovasc Interv. 2021 Mar 22;14(6):639-648. doi: 10.1016/j.jcin.2020.12.011. JACC Cardiovasc Interv. 2021. PMID: 33727005 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
